Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alomfilimab +/- Atezolizumab in Advanced Malignancies
NCT03829501Phase 2Terminated
- Sponsor
- Kymab
- Start
- Jan 2019
- Primary completion
- Oct 2024
- Modality
- Monoclonal Antibodies
- Countries
- 6
01
Overview
A Phase 2 trial of alomfilimab in non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), hepatocellular carcinoma (HCC), melanoma, Cervical Cancer (CC), sponsored by Kymab. Started Jan 2019; status: terminated.
02
Drugs
alomfilimab
03
Conditions
non-small cell lung cancer (NSCLC)head and neck squamous cell carcinoma (HNSCC)hepatocellular carcinoma (HCC)melanomaCervical Cancer (CC)
Beyond the preview
Go deeper on NCT03829501.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03829501.